{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-019130","form_type":"8-K","ticker":"DTIL","cik":"0001357874","company_name":"PRECISION BIOSCIENCES INC","filed_at":"2023-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:38.553329+00:00","generated_at":"2026-06-15T08:35:24.271886+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Precision BioSciences Q1 net loss narrows to $25.1M; cash runway through Q1 2025","bullets":["Net loss of $25.1M ($0.23/sh) vs $28.2M ($0.46/sh) in Q1 2022; revenue rose to $8.8M from $3.3M on Novartis agreement.","Cash and equivalents $158M; expects runway through Q1 2025.","Azer-cel: 7 patients in expansion cohort; PBCAR19B: 7 at Dose Level 2; updates expected May 2023.","In vivo: PBGENE-HBV targeting CTA/IND in 2024; DMD data at ASGCT; R&D Day mid-2023.","IP: Patent allowed for PCSK9-specific ARCUS nuclease for cardiovascular and gene insertion."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-019130","json":"https://secwatch.observer/filing/0000950170-23-019130.json","markdown":"https://secwatch.observer/filing/0000950170-23-019130.md","text":"https://secwatch.observer/filing/0000950170-23-019130.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1357874/000095017023019130/0000950170-23-019130-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1357874/000095017023019130/dtil-20230509.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T08:35:24.271886+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2f8c907fc1a15bc226112742a684a15bcb8b18cd","claim":"PRECISION BIOSCIENCES INC reported financial results for the first quarter ended March 31, 2023.","evidence_excerpt":"On May 9, 2023, Precision BioSciences, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1357874/000095017023019130/0000950170-23-019130-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}